The landscape of managing diabetes is changing with the emergence of transdermal GLP-1 delivery . These innovative devices offer a potentially less invasive alternative to shots for individuals living with type 2 diabetes . Such a system deliver a GLP-1 agonist directly through the skin , avoiding the necessity for frequent injections and possibly